V Speirs1, M J Kerin. 1. Medical Research Laboratory and Academic Surgical Unit, University of Hull, Hull, UK.
Abstract
BACKGROUND: Endocrine therapy for breast cancer is now well established and with the identification of a second oestrogen receptor, ERbeta, 3 years ago it is timely to review the possible significance of this receptor in breast cancer management. METHODS: An up-to-date review of the current literature concerning the role and possible implications of ERbeta in human breast cancer was undertaken. RESULTS: Wild-type and variant ERbeta are expressed in human breast tumours. Expression of ERbeta correlates with accepted prognostic indicators including lymph node status and tumour grade. Furthermore, levels of ERbeta messenger RNA alter during carcinogenesis and are upregulated in breast tumours that develop antioestrogen resistance. CONCLUSION: ERbeta has potential as a novel clinical prognostic marker in breast cancer, particularly in determining tumours that are resistant to tamoxifen.
BACKGROUND: Endocrine therapy for breast cancer is now well established and with the identification of a second oestrogen receptor, ERbeta, 3 years ago it is timely to review the possible significance of this receptor in breast cancer management. METHODS: An up-to-date review of the current literature concerning the role and possible implications of ERbeta in humanbreast cancer was undertaken. RESULTS: Wild-type and variant ERbeta are expressed in humanbreast tumours. Expression of ERbeta correlates with accepted prognostic indicators including lymph node status and tumour grade. Furthermore, levels of ERbeta messenger RNA alter during carcinogenesis and are upregulated in breast tumours that develop antioestrogen resistance. CONCLUSION:ERbeta has potential as a novel clinical prognostic marker in breast cancer, particularly in determining tumours that are resistant to tamoxifen.
Authors: E V Jensen; G Cheng; C Palmieri; S Saji; S Mäkelä; S Van Noorden; T Wahlström; M Warner; R C Coombes; J A Gustafsson Journal: Proc Natl Acad Sci U S A Date: 2001-12-04 Impact factor: 11.205
Authors: L C Dorssers; S Van der Flier; A Brinkman; T van Agthoven; J Veldscholte; E M Berns; J G Klijn; L V Beex; J A Foekens Journal: Drugs Date: 2001 Impact factor: 9.546
Authors: Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue Journal: Clin Med Insights Oncol Date: 2010-04-20
Authors: David G Cox; Philip Bretsky; Peter Kraft; Paul Pharoah; Demetrius Albanes; David Altshuler; Pilar Amiano; Goran Berglund; Heiner Boeing; Julie Buring; Noel Burtt; Eugenia E Calle; Federico Canzian; Stephen Chanock; Françoise Clavel-Chapelon; Graham A Colditz; Heather Spencer Feigelson; Christopher A Haiman; Susan E Hankinson; Joel Hirschhorn; Brian E Henderson; Robert Hoover; David J Hunter; Rudolf Kaaks; Laurence Kolonel; Loic LeMarchand; Eiliv Lund; Domenico Palli; Petra H M Peeters; Malcolm C Pike; Elio Riboli; Daniel O Stram; Michael Thun; Anne Tjonneland; Ruth C Travis; Dimitrios Trichopoulos; Meredith Yeager Journal: Int J Cancer Date: 2008-01-15 Impact factor: 7.396
Authors: Blanca Murillo-Ortiz; Horacio Astudillo-De la Vega; Sebastian Castillo-Medina; J M Malacara; Luis Benitez-Bribiesca Journal: BMC Cancer Date: 2006-08-15 Impact factor: 4.430
Authors: Isabel Conde; Juan M Alfaro; Benito Fraile; Antonio Ruíz; Ricardo Paniagua; Maria I Arenas Journal: Breast Cancer Res Date: 2004-02-13 Impact factor: 6.466